Vivos Therapeutics, Inc. Operating Income Loss

• Vivos Therapeutics, Inc. showed an increase of +35.4% in Operating Income Loss from 2023 to 2024.
• This data is from Vivos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
• XBRL data for this metric is available from 2019 to 2024 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 6 years of available data (2019 to 2024), Vivos Therapeutics, Inc.'s Operating Income Loss has declined by 5.6%.
• Historical annual values: Fiscal year 2024: -$11.17 million | Fiscal year 2023: -$17.30 million | Fiscal year 2022: -$25.03 million | Fiscal year 2021: -$20.38 million | Fiscal year 2020: -$12.04 million | Fiscal year 2019: -$10.58 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026